[go: up one dir, main page]

DE69833451D1 - Behandlung der schizophrenie mit ampakinen und neuroleptika - Google Patents

Behandlung der schizophrenie mit ampakinen und neuroleptika

Info

Publication number
DE69833451D1
DE69833451D1 DE69833451T DE69833451T DE69833451D1 DE 69833451 D1 DE69833451 D1 DE 69833451D1 DE 69833451 T DE69833451 T DE 69833451T DE 69833451 T DE69833451 T DE 69833451T DE 69833451 D1 DE69833451 D1 DE 69833451D1
Authority
DE
Germany
Prior art keywords
schizophrenia
treatment
neuroleptika
ampakins
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69833451T
Other languages
English (en)
Other versions
DE69833451T2 (de
Inventor
A Johnson
A Rogers
S Lynch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Cortex Pharmaceuticals Inc
University of California Berkeley
Original Assignee
University of California
Cortex Pharmaceuticals Inc
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22050462&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69833451(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California, Cortex Pharmaceuticals Inc, University of California Berkeley filed Critical University of California
Publication of DE69833451D1 publication Critical patent/DE69833451D1/de
Application granted granted Critical
Publication of DE69833451T2 publication Critical patent/DE69833451T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69833451T 1997-10-27 1998-10-26 Behandlung der schizophrenie mit ampakinen und neuroleptika Expired - Lifetime DE69833451T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6362797P 1997-10-27 1997-10-27
US63627P 1997-10-27
PCT/US1998/022707 WO1999021422A1 (en) 1997-10-27 1998-10-26 Treatment of schizophrenia with ampakines and neuroleptics

Publications (2)

Publication Number Publication Date
DE69833451D1 true DE69833451D1 (de) 2006-04-20
DE69833451T2 DE69833451T2 (de) 2006-09-28

Family

ID=22050462

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69833451T Expired - Lifetime DE69833451T2 (de) 1997-10-27 1998-10-26 Behandlung der schizophrenie mit ampakinen und neuroleptika

Country Status (14)

Country Link
US (1) US6166008A (de)
EP (1) EP1026950B1 (de)
JP (1) JP2001520978A (de)
CN (1) CN1281335A (de)
AT (1) ATE317226T1 (de)
AU (1) AU745641B2 (de)
BR (1) BR9814106A (de)
CA (1) CA2306817A1 (de)
CY (1) CY1105557T1 (de)
DE (1) DE69833451T2 (de)
DK (1) DK1026950T3 (de)
ES (1) ES2258825T3 (de)
PT (1) PT1026950E (de)
WO (1) WO1999021422A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2138533C (en) 1992-07-24 2009-04-14 Gary S. Lynch Drugs that enhance synaptic responses mediated by ampa receptors
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
US20050020582A1 (en) * 2001-05-25 2005-01-27 Prusiner Stanley B Optically active compounds clearing malformed proteins
US20040229898A1 (en) * 2001-05-25 2004-11-18 The Regents Of The University Of California Cyclic bis-compounds clearing malformed proteins
US7320785B2 (en) * 2001-08-10 2008-01-22 The Rockefeller University Compositions and methods for modulation of DARPP-32 phosphorylation
AU2004204814B2 (en) * 2003-01-13 2009-10-08 Cortex Pharmaceuticals, Inc. Method of treating cognitive decline due to sleep deprivation and stress
WO2005013961A1 (en) * 2003-07-17 2005-02-17 Eli Lilly And Company Combination therapy for treatment of cognitive disorders or psychoses
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
CA2536975A1 (en) * 2003-08-28 2005-03-17 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
GB0325175D0 (en) * 2003-10-28 2003-12-03 Novartis Ag Organic compounds
JP2007519733A (ja) * 2004-01-26 2007-07-19 コーテックス ファーマシューティカルズ インコーポレーティッド アンパカインにより誘導されるシナプス応答促通のコリンエステラーゼ阻害剤による増強方法
US8415298B2 (en) 2004-06-21 2013-04-09 The Board Of Trustees Of The Leland Stanford Junior University Of Stanford Administration of FGF2 for treamtent of anxiety
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
JP2008514612A (ja) * 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US7396829B2 (en) * 2005-02-24 2008-07-08 Nitromed, Inc. Nitric oxide enhancing diuretic compounds, compositions and methods of use
ME02051B (me) 2005-04-13 2015-05-20 Astex Therapeutics Ltd Derivati hidroksibenzamida i njihova primena kao inhibitora hsp90
KR20060119373A (ko) * 2005-05-20 2006-11-24 엘지전자 주식회사 컴퓨터 시스템과 시스템 소프트웨어 설치방법 및 휴대용컴퓨터의 소프트웨어 설치방법
EP1951908B1 (de) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Verfahren in zusammenhang mit diagnose und behandlung von depressionen
WO2007060144A2 (en) * 2005-11-22 2007-05-31 Neurosearch A/S Novel quinoxaline derivatives and their medical use
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US20080176793A1 (en) * 2006-09-18 2008-07-24 The Regents Of The University Of California Upregulating activity or expression of bdnf to mitigate cognitive impairment in asymptomatic huntington's subjects
WO2008044054A2 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in therapy
JP5410285B2 (ja) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
EP2073807A1 (de) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmazeutische kombinationen
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073803B1 (de) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmazeutische kombinationen
EP2073802A1 (de) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmazeutische kombinationen
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
US20090006902A1 (en) * 2007-06-29 2009-01-01 International Business Machines Corporation Methods, systems, and computer program products for reporting fru failures in storage device enclosures
KR20100045507A (ko) 2007-08-10 2010-05-03 코텍스 파마슈티칼스, 인크. 글루타메이트성 시냅스 반응을 향상시키기 위한 비시클릭 아미드
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US8071914B2 (en) * 2007-12-26 2011-12-06 Noboru Oshima Heating apparatus
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
JP2012516845A (ja) * 2009-02-02 2012-07-26 コーテックス ファーマシューティカルズ， インコーポレイテッド グルタミン酸作動性シナプス反応を増強するための二環式アミド誘導体
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
EP2544688B1 (de) 2010-03-02 2016-09-07 President and Fellows of Harvard College Verfahren und zusammensetzungen zur behandlung des angelman-syndroms
EP2801377B1 (de) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel enthaltend Zellen zur lokalen Freisetzung von Wachstumsfaktoren zur Rückgewinnung der Bewegungsfähigkeit nach einem Schlaganfall
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) * 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
EP2854836B1 (de) 2012-06-05 2018-04-04 The Board of Trustees of The Leland Stanford Junior University Ncam-peptidmimetika zur behandlung von depression
LT3781561T (lt) 2018-04-18 2024-07-10 Constellation Pharmaceuticals, Inc. Metilą modifikuojančių fermentų moduliatoriai, kompozicijos ir jų naudojimas
WO2019226491A1 (en) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
PE20220562A1 (es) 2019-07-24 2022-04-13 Constellation Pharmaceuticals Inc Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5312819A (en) * 1990-08-20 1994-05-17 Sandoz Ltd. Pharmaceutical compositions comprising clozapine and a radical scavenger
US5447948A (en) * 1992-05-07 1995-09-05 Yale University Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia
GB9507230D0 (en) * 1995-04-07 1995-05-31 Inst Of Psychiatry Novel method
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
EP1026950A1 (de) 2000-08-16
JP2001520978A (ja) 2001-11-06
DE69833451T2 (de) 2006-09-28
CY1105557T1 (el) 2010-07-28
US6166008A (en) 2000-12-26
EP1026950A4 (de) 2004-07-07
WO1999021422A1 (en) 1999-05-06
DK1026950T3 (da) 2006-06-26
CA2306817A1 (en) 1999-05-06
AU1365899A (en) 1999-05-17
BR9814106A (pt) 2000-10-03
ES2258825T3 (es) 2006-09-01
AU745641B2 (en) 2002-03-28
HK1030338A1 (en) 2001-05-04
PT1026950E (pt) 2006-06-30
ATE317226T1 (de) 2006-02-15
CN1281335A (zh) 2001-01-24
EP1026950B1 (de) 2006-02-08

Similar Documents

Publication Publication Date Title
DE69833451D1 (de) Behandlung der schizophrenie mit ampakinen und neuroleptika
DK0751939T3 (da) Naphthylamider som centralnervesystemmidler
DE69429524D1 (de) Aminocyclohexylester und ihre anwendung
CY1115759T1 (el) Αντιβιοτικες συνθεσεις για θεραπεια του οφθαλμου
DE60024588D1 (de) Substituierte porphyrine und deren therapeutische verwendungen
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DE69625518D1 (de) Wirkstoff zur behandlung neurodegenerativer störungen
ATE256671T1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)- piperazin-derivate
BR9509994A (pt) Derivados heterocíclicos aromáticos como inibidores de enzimas
SV1999000102A (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa. ref. pcs 9475 afae/bb.
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ID25856A (id) Senyawa-senyawa baru
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
DE60304695D1 (de) 7-ARYLSULFONAMID-2,3,4,5-TETRAHYDRO-1H-BENZOiDöAZEPINE MIT 5-HT6 REZEPTOR AFFINITÄT ZUR BEHANDLUNG VON ZENTRALNERVENSYSTEMERKRANKUNGEN
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
DE69526584D1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
DE69736180D1 (de) Behandlung von manischen erkrankungen
TR200000916T2 (tr) İkameli piperidin türevleri.
DE60003214D1 (de) Benz[f]indole zur verwendung in der behandlung von 5ht-rezeptor relatierten störungen

Legal Events

Date Code Title Description
8363 Opposition against the patent